Urticaria, angioedema, and anaphylaxis

Clinical Immunology: Principles and Practice: Fourth Edition

Volumn , Issue , 2013, Pages 506-521

  Borzova, Elena ^a   Grattan, Clive E H ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84943302820     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7234-3691-1.00055-6     Document Type: Chapter

References (48)

1. Zuberbier T., Binslev-Jensen C., Canonica W., et al. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy 2006, 61:316-320.
2. Urticaria 1998, Springer-Verlag, Berlin. B.M. Henz, T. Zuberbier, J. Grabbe (Eds.).
3. Urticaria and angioedema 2004, Marcel Dekker, New York. M.W. Greaves, A. Kaplan (Eds.).
4. Beltrani V.S. An overview of chronic urticaria. Clin Rev Allergy Immunol 2002, 23:147-169.
5. Aydogan K., Karadogan S.K., Akdag I., et al. HLA class I and class II antigens in Turkish patients with chronic ordinary urticaria. Clin Exp Dermatol 2006, 31:424-429.
6. O'Donnell B.F., O'Neill C.M., Francis D.M., et al. Human leucocyte antigen class II associations in chronic idiopathic urticaria. Br J Dermatol 1999, 140:853-858.
7. Oztas P., Onder M., Gonen S., et al. Is there any relationship between human leucocyte antigen class II and chronic urticaria (chronic urticaria and HLA class II)?. Yonsei Med J 2004, 45:392-395.
8. Kim S.H., Choi J.H., Lee K.W., et al. The human leucocyte antigen-DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria. Clin Exp Allergy 2005, 35:339-344.
9. Grattan C.E.H. The urticaria spectrum: recognition of clinical patterns can help management. Clin Exp Dermatol 2004, 29:217-221.
10. Maurer M., Metz M. The status quo and quo vadis of mast cells. Exp Dermatol 2005, 14:923-929.
11. Hennino A., Berard F., Guillot I., et al. Pathophysiology of urticaria. Clin Rev Allergy Immunol 2006, 30:3-11.
12. Church M.K., el-Lati S., Caulfield J.P. Neuropeptide-induced secretion from human skin mast cells. Int Arch Allergy Appl Immunol 1991, 94:310-318.
13. Sabroe R.A., Greaves M.W. Chronic idiopathic urticaria with functional autoantibodies: 12 years on. Br J Dermatol 2006, 154:813-819.
14. Kaplan A.P. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004, 114:465-474.
15. Puccetti A., Bason C., Simeoni S., et al. In chronic idiopathic urticaria autoantibodies against Fc epsilonRII/CD23 induce histamine release via eosinophil activation. Clin Exp Allergy 2005, 35:1599-1607.
16. Zuberbier T. The role of allergens and pseudoallergens in urticaria. J Investig Dermatol Symp Proc 2001, 6:132-134.
17. Grattan C.E. Aspirin sensitivity and urticaria. Clin Exp Dermatol 2003, 28:123-127.
18. Kozel M.M., Sabroe R.A. Chronic urticaria: aetiology, management and current and future treatment options. Drugs 2004, 64:2515-2536.
19. Buhner S., Reese I., Kuehl F., et al. Pseudoallergic reactions in chronic urticaria are associated with altered gastroduodenal permeability. Allergy 2004, 59:1118-1123.
20. Wanderer A.A., Hoffman H.M. The spectrum of acquired and familial cold-induced urticaria/urticaria-like syndromes. Immunol Allergy Clin North Am 2004, 24:259-286.
21. Davis M.D., Brewer J.D. Urticarial vasculitis and hypocomplementemic urticarial vasculitis syndrome. Immunol Allergy Clin North Am 2004, 24:183-213.
22. Frigas E., Nzeako U.C. Angioedema. Pathogenesis, differential diagnosis, and treatment. Clin Rev Allergy Immunol 2002, 23:217-231.
23. Almerigogna F., Giudizi M.G., Capella F., et al. Schnitzler's syndrome: what's new?. J Eur Acad Dermatol Venereol 2002, 16:214-219.
24. Kozel M.M., Bossuyt P.M., Mekkes J.R., et al. Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: a systematic review. J Am Acad Dermatol 2003, 48:409-416.
25. Asero R., Lorini M., Chong S.U., et al. Assessment of histamine-releasing activity of sera from patients with chronic urticaria showing positive autologous skin test on human basophils and mast cells. Clin Exp Allergy 2004, 34:1111-1114.
26. Grattan C.E., Powell S., Humphreys F. British Association of Dermatologists. Management and diagnostic guidelines for urticaria and angioedema. Br J Dermatol 2001, 144:708-714.
27. Zuberbier T., Binslev-Jensen C., Canonica W., et al. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy 2006, 61:321-331.
28. Borzova E., Grattan C. Urticaria: current and future treatments. Expert Rev Dermatol 2007, 2:317-334.
29. Zuraw B.L. Hereditary angioedema. N Engl J Med 2008, 359:1027-1036.
30. Gompels M.M., Lock R.J., Abinun M., et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005, 139:379-394.
31. Matasar M.J., Neugut A.I. Epidemiology of anaphylaxis in the United States. Curr Allergy Asthma Rep 2003, 3:30-35.
32. Kemp S.F., Lockey R.F. Pathophysiology and organ damage in anaphylaxis. Anaphylaxis and hypersensitivity reactions 2011, 33-46. Humana Press. 1st ed. M.C. Castells (Ed.).
33. Moneret-Vautrin D.A., Morisset M., Flabbee J., et al. Epidemiology of life-threatening and lethal anaphylaxis: a review. Allergy 2005, 60:443-451.
34. Pumphrey R. Anaphylaxis: can we tell who is at risk of a fatal reaction?. Curr Opin Allergy Clin Immunol 2004, 4:285-290.
35. Sheikh A., Alves B. Age, sex, geographical and socio-economic variations in admissions for anaphylaxis: analysis of four years of English hospital data. Clin Exp Allergy 2001, 31:1571-1576.
36. Mullins R.J. Anaphylaxis: risk factors for recurrence. Clin Exp Allergy 2003, 33:1033-1040.
37. Sheikh A., Alves B. Hospital admissions for acute anaphylaxis: time trend study. Br Med J 2000, 320:1441.
38. Novartis Foundation Anaphylaxis 257 2004, Wiley, Chichester.
39. Sampson H.A., Munoz-Furlong A., Campbell R.L., et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006, 117:391-397.
40. Sampson H.A. Anaphylaxis and emergency treatment. Pediatrics 2003, 111:1601-1608.
41. Leone R., Conforti A., Venegoni M., et al. Drug-induced anaphylaxis: case/non-case study based on an Italian pharmacovigilance database. Drug Safe 2005, 28:547-556.
42. Mertes P.M., Laxenaire M.C., Lienhart A., et al. Reducing the risk of anaphylaxis during anaesthesia: guidelines for clinical practice. J Investig Allergol Clin Immunol 2005, 15:91-101.
43. Salama A., Temmesfeld B., Hippenstiel S., et al. A new strategy for the prevention of IgA anaphylactic transfusion reactions. Transfusion 2004, 44:509-511.
44. Akin C., Scott L.M., Kocabas C.N., et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood 2007, 110(7):2331-2333.
45. Brown S.G. Anaphylaxis: clinical concepts and research priorities. Emerg Med Australas 2006, 18:155-169.
46. Bernstein D.I. Pharmacological management of acute anaphylaxis. Anaphylaxis and hypersensitivity reactions 2011, 285-295. Humana Press. 1st ed. M.C. Castells (Ed.).
47. Lieberman P. Use of epinephrine in the treatment of anaphylaxis. Curr Opin Allergy Clin Immunol 2003, 3:313-318.
48. Simons F.E.R., Ardusso L.R.F., Bilo M.B., et al. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol 2011, 127:587-593. e22.